Investor Centre

• Collaboration with research team led by Professor Fiona Wood AM doses first patients in trial of 50 patients with established scars
• 3-month placebo-controlled study to report safety and tolerability endpoints as well as measures of scar structure and appearance in 2H 2022
• PXS-6302 is a first in class topical inhibitor of the lysyl oxidase enzymes that are involved in formation and maintenance of scars; a potential breakthrough treatment for patients with problematic scars in a market estimated at US$3.5 billion per year

Pharmaxis Ltd (ASX: PXS) will release its Quarterly Shareholder Update on the morning of 31 January 2022.

Investors and analysts are invited to participate in a virtual investor briefing by the Company’s chief executive officer Mr Gary Phillips at 11.00am AET on Monday 31 January 2022.

The event will consist of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees.

The event is free to attend, and investors should register in advance using the following registration link:  

https://www.pharmaxis.com.au/investor-centre/investor-briefing/

Upon registration, instructions for joining the session will be sent via email.

To ensure as many questions as possible can be responded to in the allotted time, Pharmaxis welcomes investors to pre-submit questions by emailing them to: david.mcgarvey@pharmaxis.com.au

• Associate Professor Thomas Cox from the Garvan Institute of Medical Research has been awarded an $827,500 NHMRC Development Grant to lead a multidisciplinary team investigating PXS-5505 as a promising new treatment approach for pancreatic cancer.
• Professor Fiona Wood and Associate Professor Mark Fear of the University of Western Australia have been awarded a $590,200 NHMRC Drug Development Grant to work on a novel small molecule from the Pharmaxis pre-clinical pipeline for tissue repair and inflammatory skin disease.